MEI Pharma Inc (NASDAQ:MEIP) was the target of a large decrease in short interest in November. As of November 29th, there was short interest totalling 249,100 shares, a decrease of 20.0% from the November 14th total of 311,400 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average daily volume of 193,600 shares, the days-to-cover ratio is presently 1.3 days.

Large investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new position in MEI Pharma during the 2nd quarter worth approximately $151,000. Jane Street Group LLC acquired a new stake in shares of MEI Pharma in the 2nd quarter valued at approximately $361,000. Northern Trust Corp boosted its holdings in shares of MEI Pharma by 92.6% in the 2nd quarter. Northern Trust Corp now owns 119,007 shares of the company’s stock valued at $298,000 after buying an additional 57,211 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of MEI Pharma by 13.8% in the 2nd quarter. Vanguard Group Inc. now owns 2,849,609 shares of the company’s stock valued at $7,124,000 after buying an additional 344,986 shares during the last quarter. Finally, Algert Global LLC boosted its holdings in shares of MEI Pharma by 105.4% in the 2nd quarter. Algert Global LLC now owns 38,797 shares of the company’s stock valued at $97,000 after buying an additional 19,907 shares during the last quarter. 57.77% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:MEIP remained flat at $$1.95 during trading hours on Thursday. The company’s stock had a trading volume of 152,249 shares, compared to its average volume of 261,919. MEI Pharma has a 52-week low of $1.44 and a 52-week high of $3.41. The company’s fifty day simple moving average is $1.86 and its 200 day simple moving average is $1.98. The stock has a market capitalization of $140.68 million, a PE ratio of -3.15 and a beta of 1.72.

MEIP has been the subject of a number of research reports. Zacks Investment Research raised MEI Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday. ValuEngine raised MEI Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. MEI Pharma currently has a consensus rating of “Buy” and a consensus price target of $6.00.

About MEI Pharma

MEI Pharma, Inc, a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.

Featured Article: What is a growth and income fund?

Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.